期刊
CLINICAL LABORATORY
卷 66, 期 9, 页码 1823-1834出版社
CLIN LAB PUBL
DOI: 10.7754/Clin.Lab.2020.200127
关键词
breast cancer; exosome; miR-17-5p; diagnostics; biomarker
资金
- Public Technology Research Project of Zhejiang Province [LGF 18H200006]
- Medicines Health Technology Plan Project of Zhejiang Province [2018 PY073]
Background: The biological role of exosomes has attracted widespread attention in various fields of biomedicine. Exosome-delivered microRNAs (miRNAs) play crucial roles in cancer diagnosis. The aim of our study was to examine whether serum exosomal miR-17-5p could be identified as a diagnostic biomarker for breast cancer (BC). Methods: Eighty-three patients diagnosed with BC and thirty-four healthy women (controls) were included in this study. The expression level of serum exosomal miR-17-5p was identified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and calculated by 2(-Delta Delta Cq) method. Results: Reduced level of exosomal miR-17-5p in serum from BC patients was found compared with healthy controls. In addition, miR-17-5p also had low expression in 34 pairs of tissue and serum samples. MiR-17-5p was highly concentrated in serum exosomes and the expression level was stable. In addition, the exosomal miR-17-5p could distinguish BC from healthy controls with the area under the ROC curve (AUC) of 0.784 (p < 0.0001, sensitivity = 66.67%, specificity = 83.95%). The sensitivity and specificity of miR-17-5p were superior to conventional serum biomarkers CEA, CA125, and CA153. We predicted target genes of miR-17-5p were also mainly involved in cancer-related pathways. Conclusions: In conclusion, our findings strongly suggested that serum exosomal miR-17-5p could serve as a novel diagnostic biomarker for BC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据